This #BladderCancer Awareness Month, we are proud to support Bladder Cancer Advocacy Network’s Walk to End Bladder Cancer to honor the survivors, caregivers, family, and medical professionals who grapple with the realities of this disease every day.

We are pleased to announce our $555 million financing to support our ongoing pipeline progress. Thanks to our investors for their confidence in the potential of our Bicycle® platform to create new medicines for #cancer and other diseases. Read here: bit.ly/44RO2OU

At #ASCO24, we are proud to present two posters about the emerging differentiated safety and tolerability profiles of our Bicycle® molecules and our Phase 2/3 Duravelo-2 trial for #bladdercancer. See you soon: bit.ly/44V0hu6 #cancer #solidtumors

We’re welcoming our most recent new hires who joined #TeamBicycle in May. We are excited to have you on our Clinical, Medical and Finance teams! Learn more about our careers and culture: bit.ly/3TS7ZA8.

Our CEO Kevin Lee recently spoke to Biotech Strategy's Sally Church about how we're harnessing the power of bicyclic peptides to develop a variety of highly specific, targeted therapies to treat #cancer and other diseases. Read more here: bit.ly/4aVjkGc.

Three investor conferences in three weeks – what a whirlwind! Thanks to Jefferies , Goldman Sachs and TD Cowen for hosting our team. Replays of the fireside chats and presentations are available on our website: bit.ly/4eldP6n.

We’re welcoming our most recent new hires who joined #TeamBicycle in June. We are excited to have you on our Clinical Operations, CMC and Medical Affairs teams! Learn more about our careers and culture: bit.ly/3TS7ZA8.

At Bicycle Therapeutics, we are harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines for #cancer and other diseases. Watch this video to learn more.

At Bicycle Therapeutics, we are harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines for #cancer and other diseases. Watch this video to learn more.

We recently held our UK Science Fair, an annual event hosted by our Research Team to showcase the innovative work being conducted at our company, and the breadth and potential of our Bicycle® platform. Congrats to this year’s winners, and a big thanks to the organizing committee!

Congrats to our #TeamBicycle colleague Jennifer Perry on her promotion to Chief Strategy Officer! Jennifer will oversee our corporate & portfolio strategy while fulfilling her existing responsibilities as Head of Commercial. We look forward to seeing her succeed in this new role.

At #ESMO24, we are excited to present four posters highlighting our progress in developing Bicycle® molecules for the potential treatment of #cancer, including clinical data updates for zelenectide pevedotin (formerly BT8009), BT5528 and BT7480. More here: bit.ly/3SjWd1v

Ever wonder how we came up with the name zelenectide pevedotin for our lead investigational #cancer therapy? It turns out there is important meaning behind the different components of the name. Check out the video below.

Every year, we bestow Achievement Awards to recognize those on #TeamBicycle who have made a significant impact to help us reach our company goals. We are proud of those who have received bronze, silver and gold awards over the past year. Thanks for your dedication to our mission!

Today we reported recent business progress and second quarter 2024 financial results. Read our press release here: bit.ly/3LUxxJl.

We are pleased to welcome the inaugural members of our new Clinical Advisory Board: Dr. Charles Swanton, Dr. Toni K. Choueiri, Prof. Sherene Loi and Prof. Solange Peters. Their insights will be invaluable as we advance our clinical programs in #oncology.

At two investor conferences in September, our management team will discuss upcoming data updates as we leverage our Bicycle® platform technology to develop innovative medicines for #cancer and other diseases. Get the details here: bit.ly/3SX5nkM.

A huge congrats to our scientific co-founder Sir Gregory Winter for being awarded The Royal Society’s Copley Medal! He joins Louis Pasteur, Dorothy Hodgkin, Albert Einstein and Charles Darwin as recipients of this esteemed award. #Science

We’re welcoming our most recent new hires who joined #TeamBicycle. We are excited to have you on our Research, Clinical, Medical, Manufacturing and Supply, and IT teams! Learn more about our careers and culture: bit.ly/3TS7ZA8.

Ph1 dose escalation results for investigational Bicycle® Toxin Conjugate BT5528 are now online in the Journal of Clinical Oncology: ascopubs.org/doi/10.1200/JC…. Many thanks to the patients, physicians & clinical site staff for their contributions. Look for updated data at #ESMO24.